Publications by authors named "J Zijlmans"
Background: The FAIR (Findable, Accessible, Interoperable, Reusable) data principles are a guideline to improve the reusability of data. However, properly implementing these principles is challenging due to a wide range of barriers.
Objectives: To further the field of FAIR data, this study aimed to systematically identify barriers regarding implementing the FAIR principles in the area of child and adolescent mental health research, define the most challenging barriers, and provide recommendations for these barriers.
Background: The COVID-19 pandemic negatively affected child and adolescent mental health and at the end of the pandemic (April 2022) child mental health had not returned to pre-pandemic levels. We investigated whether this observed increase in mental health problems has continued, halted, or reversed after the end of the pandemic in children from the general population and in children in psychiatric care.
Methods: We collected parent-reported and child-reported data at two additional post-pandemic time points (November/December 2022 and March/April 2023) in children (8-18 years) from two general population samples ( = 818-1056 per measurement) and one clinical sample receiving psychiatric care ( = 320-370) and compared these with data from before the pandemic.
Article Synopsis
- - The study assessed how family history of dementia relates to brain structure and cognitive performance in parents (average age 47) and their children (average age 9-13) using data from the Generation R Study.
- - Out of 1,259 parents, 8.6% reported having a parental history of dementia, while 8.4% of children had a grandparental history, but there were no significant cognitive differences between those with and without such histories, except for slightly worse manual dexterity in the parents.
- - The findings indicate that while family history of dementia could impact manual skills in mid-life adults, it does not significantly affect cognitive ability or brain structure in either group, suggesting a link primarily to
The positive results of MDMA from Phase 2 and 3 clinical trials in MDMA-assisted therapy (MDMA-AT) for the treatment of post-traumatic stress disorder (PTSD) call for a critical evaluation of its regulatory status within the European mental healthcare system. This is driven by the recent submission of MDMA-AT for FDA approval in the United States. Unless coordinated efforts in the European regulatory landscape start, there may be potential divergences in national regulatory strategies.
View Article and Find Full Text PDFMDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.
Eur Child Adolesc Psychiatry
November 2024
Article Synopsis
- MDMA-assisted psychotherapy (MDMA-AP) is a promising treatment for PTSD that may soon be approved for adults and could also be beneficial for trauma-exposed adolescents.
- The use of MDMA in therapy may help adolescents process trauma, strengthen their relationship with therapists, and improve coping with PTSD symptoms.
- There’s a need for tailored adaptations of MDMA-AP for adolescents, while also considering risks and advocating for clinical trials to test its safety and effectiveness in this age group.